Changes in neutrophil, lymphocyte, platelet ratios and their relationship with NIHSS after rtPA and/or thrombectomy in ischemic stroke

Ischemic stroke accounts for about 80% of cerebrovascular diseases and causes serious neurological deficits in patients.1 For maximum benefit from ischemic stroke treatment, intravenous (IV) recombinant tissue plasminogen activator (rtPA) should be given or thrombectomy be performed as soon as possible.2 The inflammatory reaction following acute cerebral ischemia enlarges the infarct area and aggravates neurological deficit. In ischemic should tissue injury that begins with decreased blood flow to the tissue and oxygen deficiency, reperfusion occurs with rtPA or thrombectomy treatment and the damaged tissues are re-oxygenated.
Source: Journal of Stroke and Cerebrovascular Diseases - Category: Neurology Authors: Source Type: research